close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

5.21 -2.98

Strong Buy

Prijsupdate 25 mrt 2026, 19:58 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.06

Max

5.67

Belangrijke statistieken

By Trading Economics

Inkomsten

-69M

-102M

Verkoop

-10M

34M

EPS

-5.69

Winstmarge

-299.886

Werknemers

228

EBITDA

4.7M

-18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+230.13% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-35M

122M

Vorige openingsprijs

8.19

Vorige sluitingsprijs

5.21

Nieuwssentiment

By Acuity

24%

76%

49 / 350 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mrt 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Infosys Agrees to Acquire Stratus

DJ

Lezen

25 mrt 2026, 23:58 UTC

Winsten

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

DJ

Lezen

25 mrt 2026, 23:58 UTC

Winsten

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

DJ

Lezen

25 mrt 2026, 23:57 UTC

Winsten

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

DJ

Lezen

25 mrt 2026, 23:57 UTC

Winsten

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

DJ

Lezen

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

DJ

Lezen

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

DJ

Lezen

25 mrt 2026, 23:41 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

DJ

Lezen

25 mrt 2026, 23:41 UTC

Winsten

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

DJ

Lezen

25 mrt 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Declines on Possible Technical Correction -- Market Talk

DJ

Lezen

25 mrt 2026, 22:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

25 mrt 2026, 22:08 UTC

Marktinformatie

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

DJ

Lezen

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

DJ

Lezen

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

DJ

Lezen

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

DJ

Lezen

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

DJ

Lezen

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

DJ

Lezen

25 mrt 2026, 21:58 UTC

Marktinformatie

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

DJ

Lezen

25 mrt 2026, 21:37 UTC

Marktinformatie

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

DJ

Lezen

25 mrt 2026, 21:14 UTC

Acquisities, Fusies, Overnames

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

DJ

Lezen

25 mrt 2026, 21:13 UTC

Acquisities, Fusies, Overnames

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

DJ

Lezen

25 mrt 2026, 21:12 UTC

Acquisities, Fusies, Overnames

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

DJ

Lezen

25 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

25 mrt 2026, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

DJ

Lezen

25 mrt 2026, 20:33 UTC

Acquisities, Fusies, Overnames

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

DJ

Lezen

25 mrt 2026, 20:31 UTC

Winsten

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

DJ

Lezen

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

DJ

Lezen

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

DJ

Lezen

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

DJ

Lezen

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

230.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 17.2 USD  230.13%

Hoogste 28 USD

Laagste 8 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

49 / 350 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

914.82

↑ +1.5%

JNJ

Johnson and Johnson

239.95

↑ +2.09%

ABBV

AbbVie Inc

206.56

↑ +0.92%

NVS

Novartis AG

150.73

↑ +1.58%

MRK

Merck & Co Inc.

119.31

↑ +2.59%
help-icon Live chat